ClinicalTrials.gg
RecruitingNCT03836521Updated Feb 11, 2019

Bicuspid Aortic Valve Stenosis Transcatheter Aortic Valve Replacement Registry

An observational study in Bicuspid Aortic Valve, sponsored by Cedars-Sinai Medical Center. Recruiting at 1 site in United States. Open to participants aged 19 Years to 129 Years. Per ClinicalTrials.gov, last updated 2019-02-11.

Sponsored by Cedars-Sinai Medical Center · Observational

How we know

From the registry’s dates

  • Started Aug 2016; still recruiting 10 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,000
Ages
19 Years to 129 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Bicuspid Aortic Valve Disease with a site in United States — 6 open to participants now, 10 under way, none of them phase 3. Bicuspid Aortic Valve Disease · United States.

Planned enrollment
7th of 12
2,000 · median 2,500
Started
2016
with 2 others
Observational
12 of 19
4 open now
Registered
16th of 19
by date
Lead sponsor
3 of 19
Cedars-Sinai Medical Center

Among the 19 studies in Bicuspid Aortic Valve Disease with a site in United States, this one is the 7th largest by planned enrollment of the 12 observational ones that give a count, is one of 3 that started in 2016, is one of 12 observational ones, and was the 16th registered.

Bicuspid Aortic Valve Disease

62 studies on the registry are indexed under Bicuspid Aortic Valve Disease; 21 are open to participants now.

Browse Bicuspid Aortic Valve Disease studies →

Open to participants now

6 of the 19 studies in Bicuspid Aortic Valve Disease with a site in United States are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 17 Bicuspid Aortic Valve Disease studies recruiting now, 12 (71%) set no upper age limit and 3 (18%) stop at 75 or younger; 5 take children under 18; 2 take healthy volunteers.

This study: 19 Years to 129 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Bicuspid Aortic Valve Disease with a site in United States, or all of them as a file.
02

Study summary

The objective of this study is to evaluate the procedural and clinical outcomes of patients with bicuspid aortic valve stenosis undergoing transcatheter aortic valve replacement.

03

Conditions studied

  • Bicuspid Aortic Valve
04

Who can participate

Ages eligible
19 Years to 129 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All consecutive patients presenting with severe and symptomatic bicuspid aortic valve stenosis or mixed disease

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age≥18 years.
  2. Severe aortic stenosis with bicuspid anatomy.
  3. ≥2 and/or syncope and/or angina.
  4. Patient judged by the Heart Team as indicated for TAVR.

Exclusion criteria

Exclusion Criteria:

  1. Age \<18 years
  2. Asymptomatic patients
  3. Pure aortic regurgitation.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,000 participants (estimated)
Patient registry
No

Interventions

  • DeviceTranscatheter aortic valve replacement
06

What researchers measure

Primary outcomes

  1. Death

    Death from any cause

    Time frame: 1 month

  2. Death

    Death from any cause

    Time frame: 1 year

  3. Death

    Death from any cause

    Time frame: 2 years

  4. Death

    Death from any cause

    Time frame: 3 years

  5. Death

    Death from any cause

    Time frame: 4 years

  6. Death

    Death from any cause

    Time frame: 5 years

Secondary outcomes

  1. Death from cardiac cause

    Death from cardiac cause

    Time frame: 1 month

  2. Death from cardiac cause

    Death from cardiac cause

    Time frame: 1 year

  3. Death from cardiac cause

    Death from cardiac cause

    Time frame: 2 years

  4. Death from cardiac cause

    Death from cardiac cause

    Time frame: 3 years

  5. Death from cardiac cause

    Death from cardiac cause

    Time frame: 4 years

  6. Death from cardiac cause

    Death from cardiac cause

    Time frame: 5 years

  7. Stroke

    disabling and non-disabling stroke

    Time frame: 1 month

  8. Stroke

    disabling and non-disabling stroke

    Time frame: 1 year

  9. Stroke

    disabling and non-disabling stroke

    Time frame: 2 years

  10. Stroke

    disabling and non-disabling stroke

    Time frame: 3 years

  11. Stroke

    disabling and non-disabling stroke

    Time frame: 4 years

  12. Stroke

    disabling and non-disabling stroke

    Time frame: 5 years

  13. Repeat hospitalization

    Number of hospitalizations

    Time frame: 1 month

  14. Repeat hospitalization

    Number of hospitalizations

    Time frame: 1 year

  15. Repeat hospitalization

    Number of hospitalizations

    Time frame: 2 years

  16. Repeat hospitalization

    Number of hospitalizations

    Time frame: 3 years

  17. Repeat hospitalization

    Number of hospitalizations

    Time frame: 4 years

  18. Repeat hospitalization

    Number of hospitalizations

    Time frame: 5 years

  19. Bleeding

    Life-threatening or major bleeding rate

    Time frame: 1 month

  20. Bleeding

    Life-threatening or major bleeding rate

    Time frame: 1 year

  21. Bleeding

    Life-threatening or major bleeding rate

    Time frame: 2 years

  22. Bleeding

    Life-threatening or major bleeding rate

    Time frame: 3 years

  23. Bleeding

    Life-threatening or major bleeding rate

    Time frame: 4 years

  24. Bleeding

    Life-threatening or major bleeding rate

    Time frame: 5 years

  25. Vascular complication

    Major vascular complication

    Time frame: 1 month

  26. Vascular complication

    Major vascular complication

    Time frame: 1 year

  27. Vascular complication

    Major vascular complication

    Time frame: 2 years

  28. Vascular complication

    Major vascular complication

    Time frame: 3 years

  29. Vascular complication

    Major vascular complication

    Time frame: 4 years

  30. Vascular complication

    Major vascular complication

    Time frame: 5 years

  31. Acute kidney injury (stage 2 or 3)

    Time frame: 1 month

  32. Acute kidney injury (stage 2 or 3)

    Time frame: 1 year

  33. Acute kidney injury (stage 2 or 3)

    Time frame: 2 years

  34. Acute kidney injury (stage 2 or 3)

    Time frame: 3 years

  35. Acute kidney injury (stage 2 or 3)

    Time frame: 4 years

  36. Acute kidney injury (stage 2 or 3)

    Time frame: 5 years

  37. Prosthetic regurgitation by Doppler echocardiography

    Time frame: at discharge

  38. Prosthetic regurgitation by Doppler echocardiography

    Time frame: 1 month

  39. Prosthetic regurgitation by Doppler echocardiography

    Time frame: 1 year

  40. Prosthetic regurgitation by Doppler echocardiography

    Time frame: 2 years

  41. Prosthetic regurgitation by Doppler echocardiography

    Time frame: 3 years

  42. Prosthetic regurgitation by Doppler echocardiography

    Time frame: 4 years

  43. Prosthetic regurgitation by Doppler echocardiography

    Time frame: 5 years

  44. Mean aortic valve gradient by Doppler echocardiography

    Time frame: 1 month

  45. Mean aortic valve gradient by Doppler echocardiography

    Time frame: 1 year

  46. Mean aortic valve gradient by Doppler echocardiography

    Time frame: 2 years

  47. Mean aortic valve gradient by Doppler echocardiography

    Time frame: 3 years

  48. Mean aortic valve gradient by Doppler echocardiography

    Time frame: 4 years

  49. Mean aortic valve gradient by Doppler echocardiography

    Time frame: 5 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Yoon SH, Kim WK, Dhoble A, Milhorini Pio S, Babaliaros V, Jilaihawi H, Pilgrim T, De Backer O, Bleiziffer S, Vincent F, Shmidt T, Butter C, Kamioka N, Eschenbach L, Renker M, Asami M, Lazkani M, Fujita B, Birs A, Barbanti M, Pershad A, Landes U, Oldemeyer B, Kitamura M, Oakley L, Ochiai T, Chakravarty T, Nakamura M, Ruile P, Deuschl F, Berman D, Modine T, Ensminger S, Kornowski R, Lange R, McCabe JM, Williams MR, Whisenant B, Delgado V, Windecker S, Van Belle E, Sondergaard L, Chevalier B, Mack M, Bax JJ, Leon MB, Makkar RR; Bicuspid Aortic Valve Stenosis Transcatheter Aortic Valve Replacement Registry Investigators. Bicuspid Aortic Valve Morphology and Outcomes After Transcatheter Aortic Valve Replacement. J Am Coll Cardiol. 2020 Sep 1;76(9):1018-1030. doi: 10.1016/j.jacc.2020.07.005. PubMed 32854836 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2016 (actual). Primary completion is estimated for Aug 2028, 144 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2019
First posted
Feb 11, 2019
StartActual
Aug 15, 2016
Primary completionEst.
Aug 15, 2028
CompletionEst.
Aug 15, 2028
Last update
Feb 11, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03836521
Responsible party
Raj Makkar (Profssor of Medicine, University of California, Cedars-Sinai Medical Center) — Principal investigator
First posted
Feb 11, 2019
Start date
Aug 15, 2016
Primary completion
Aug 15, 2028 (estimated)
Completion
Aug 15, 2028 (estimated)
Last update
Feb 11, 2019

Study contacts

Sung-Han Yoon, M.D.
Contact
Sunghan.Yoon@cshs.org
3104237426

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion